HT-ADVANCE aims to improve the personalized treatment of high blood pressure (hypertension) by using special biological markers (MOMICS) to help doctors choose the right treatment for each patient. Hypertension is a major global health risk factor, but despite several treatment options, blood pressure remains elevated in more than half of the patients. This is often because secondary forms due to an underlying and curable disease, such as endocrine hypertension (EHT), aren’t identified and treated properly. Also, different patients respond differently to the same drugs, leading to inefficient treatments being delivered.
The goal of HT-ADVANCE is to test two types of MOMICS biomarkers to:
1. Identify patients with EHT.
2. Predict how patients with primary hypertension will respond to treatment.
We believe use of MOMICS biomarkers will improve diagnosis of secondary forms of hypertension and indicate the treatment of choice for each patient. To prove this, we will conduct three clinical trials and use Artificial Intelligence to analyze genetic and metabolic data. We will also evaluate the cost-effectiveness of using these biomarkers, produce ethical and legal guidelines for the use of Artificial intelligence in the clinical setting, and create a plan to implement them in clinical practice.
The project will be carried out by several excellence hypertension centers and will build on previous successful research. We hope HT-ADVANCE will lead to more personalized, efficient, and cost-effective treatments for hypertension, for improved cure and prevention of cardiovascular and metabolic complications.
